Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.contributor.author | 이정 | * |
dc.date.accessioned | 2022-03-29T16:31:01Z | - |
dc.date.available | 2022-03-29T16:31:01Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 1999-4923 | * |
dc.identifier.other | OAK-31132 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/260929 | - |
dc.description.abstract | There are conflicting results regarding the effect of the P450 oxidoreductase (POR) *28 genotype on the tacrolimus (TAC) pharmacokinetics (PKs) during the early post-transplantation period in adult renal transplant recipients. Thus, we characterized the impact of POR*28 on TAC PKs. We conducted a systematic review on the association between POR*28 and PKs of TAC in adult renal transplant recipients. Structured searches were conducted using PubMed, Web of Science, and Embase. TAC standardized trough concentration (ng/mL per mg/kg) data were extracted. Mean differences (MD) and their corresponding 95% confidence intervals (CIs) were used to identify the differences between the POR*28 genotype and PKs of TAC. The subgroup analysis was conducted according to CYP3A5 expression status. Six studies (n = 1061) were included. TAC standardized trough concentrations were significantly lower in recipients with the POR*28 allele compared to recipients with POR*1/*1 (MD: 8.30 ng/mL per mg/kg; 95% CI: 1.93, 14.67; p = 0.01). In the subgroup analysis, TAC standardized trough concentrations were lower for subjects who were POR*28 carriers than those who were POR*1/*1 in CYP3A5 expressers (MD: 20.21 ng/mL per mg/kg; 95% CI: 16.85, 23.56; p < 0.00001). No significant difference between POR*28 carriers and POR*1/*1 was found in the CYP3A5 non-expressers. The results of our meta-analysis demonstrated a definite correlation between the POR*28 genotype and PKs of TAC. Patients carrying the POR*28 allele may require a higher dose of TAC to achieve target levels compared to those with POR*1/*1, especially in CYP3A5 expressers. © 2022 by the authors. Licensee MDPI, Basel, Switzerland. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | Kidney transplant | * |
dc.subject | Pharmacokinetics | * |
dc.subject | POR | * |
dc.subject | Tacrolimus | * |
dc.title | Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis | * |
dc.type | Review | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 14 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Pharmaceutics | * |
dc.identifier.doi | 10.3390/pharmaceutics14020261 | * |
dc.identifier.wosid | WOS:000764722900001 | * |
dc.identifier.scopusid | 2-s2.0-85124103176 | * |
dc.author.google | Lee D.-H. | * |
dc.author.google | Lee H. | * |
dc.author.google | Yoon H.-Y. | * |
dc.author.google | Yee J. | * |
dc.author.google | Gwak H.-S. | * |
dc.contributor.scopusid | 이정(57193857003) | * |
dc.date.modifydate | 20240422115307 | * |